EA201200574A1 - Терапия пирфенидоном и индукторы цитохрома р450 - Google Patents
Терапия пирфенидоном и индукторы цитохрома р450Info
- Publication number
- EA201200574A1 EA201200574A1 EA201200574A EA201200574A EA201200574A1 EA 201200574 A1 EA201200574 A1 EA 201200574A1 EA 201200574 A EA201200574 A EA 201200574A EA 201200574 A EA201200574 A EA 201200574A EA 201200574 A1 EA201200574 A1 EA 201200574A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyrphenidone
- cytochrome
- inductors
- therapy
- pirfenidone
- Prior art date
Links
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 abstract 1
- 229960003073 pirfenidone Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Abstract
Настоящее изобретение относится к способам, включающим предотвращение неблагоприятного лекарственного взаимодействия пирфенидона и индукторов CYP, таких как курение.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26675309P | 2009-12-04 | 2009-12-04 | |
| US12/684,543 US8084475B2 (en) | 2009-12-04 | 2010-01-08 | Pirfenidone therapy and inducers of cytochrome P450 |
| EP10250378A EP2308491B1 (en) | 2009-12-04 | 2010-03-03 | Pirfenidone therapy and inducers of cytochrome P450 |
| US31057510P | 2010-03-04 | 2010-03-04 | |
| CA2710014A CA2710014C (en) | 2009-12-04 | 2010-08-17 | Pirfenidone therapy and inducers of cytochrome p450 |
| PCT/US2010/058936 WO2011069089A1 (en) | 2009-12-04 | 2010-12-03 | Pirfenidone therapy and inducers of cytochrome p450 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201200574A1 true EA201200574A1 (ru) | 2012-10-30 |
| EA026869B1 EA026869B1 (ru) | 2017-05-31 |
Family
ID=42077364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201200574A EA026869B1 (ru) | 2009-12-04 | 2010-12-03 | Способ лечения идиопатического легочного фиброза |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8084475B2 (ru) |
| EP (3) | EP2377537A1 (ru) |
| JP (3) | JP5753094B2 (ru) |
| KR (2) | KR101762465B1 (ru) |
| AT (1) | ATE523197T1 (ru) |
| AU (1) | AU2010212488B2 (ru) |
| CA (1) | CA2710014C (ru) |
| CY (1) | CY1112075T1 (ru) |
| DK (1) | DK2308491T3 (ru) |
| EA (1) | EA026869B1 (ru) |
| ES (1) | ES2395159T3 (ru) |
| GE (1) | GEP20166426B (ru) |
| HK (1) | HK1151725A1 (ru) |
| HR (1) | HRP20110853T1 (ru) |
| IL (1) | IL219056A (ru) |
| MX (1) | MX2012004528A (ru) |
| NZ (1) | NZ599246A (ru) |
| PE (1) | PE20121348A1 (ru) |
| PL (1) | PL2308491T3 (ru) |
| PT (1) | PT2308491E (ru) |
| RS (1) | RS51976B (ru) |
| SG (1) | SG181128A1 (ru) |
| SI (1) | SI2308491T1 (ru) |
| SM (1) | SMT201200003B (ru) |
| TW (2) | TWI440459B (ru) |
| WO (1) | WO2011069089A1 (ru) |
| ZA (1) | ZA201202553B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
| US10092552B2 (en) | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US9907671B2 (en) | 2012-11-16 | 2018-03-06 | In Queue Innovations, Llc | Oblique expanding fusion cage device and method |
| WO2014151517A1 (en) * | 2013-03-15 | 2014-09-25 | Intermune, Inc. | Methods of improving microvascular integrity |
| EP3711715B1 (en) | 2013-03-15 | 2024-04-24 | Spine Forward, Llc | Expandable fusion cage system |
| AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| EP3126362B1 (en) | 2014-04-02 | 2022-01-12 | Intermune, Inc. | Anti-fibrotic pyridinones |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| CN111991393A (zh) * | 2019-09-26 | 2020-11-27 | 深圳先进技术研究院 | 吡非尼酮在制备防治类风湿性关节炎的药物中的应用 |
| WO2021057599A1 (zh) * | 2019-09-26 | 2021-04-01 | 深圳先进技术研究院 | 吡非尼酮在制备防治类风湿性关节炎的药物中的应用 |
| JP2023504415A (ja) | 2019-12-04 | 2023-02-03 | イドーシア ファーマシューティカルズ リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
| US20240058350A1 (en) * | 2020-12-31 | 2024-02-22 | Arena Pharmaceuticals, Inc. | Methods of Treatment |
| WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5330562A (en) * | 1993-03-12 | 1994-07-19 | Medx, Inc. | Fluidized bed scrubber for use in gas cleaning system |
| WO2004019863A2 (en) | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Combination therapy for treatment of fibrotic disorders |
| JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Ｋｄｌ株式会社 | ピリドン誘導体の溶液状医薬組成物 |
| WO2005013917A2 (en) | 2003-02-28 | 2005-02-17 | Intermune, Inc. | Combination therapy for treating alphavirus infection and liver fibrosis |
| WO2004103296A2 (en) | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| EP2390262A1 (en) | 2003-05-16 | 2011-11-30 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| US20070053877A1 (en) | 2003-08-21 | 2007-03-08 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| CN1846699A (zh) | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
| KR101294467B1 (ko) | 2005-07-25 | 2013-09-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제 |
| EP1951233B1 (en) | 2005-10-31 | 2012-03-28 | Intermune, Inc. | Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf) |
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| DE602007014113D1 (de) | 2006-12-18 | 2011-06-01 | Intermune Inc | Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten |
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
| US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
-
2010
- 2010-01-08 US US12/684,543 patent/US8084475B2/en active Active
- 2010-03-03 AT AT10250378T patent/ATE523197T1/de active
- 2010-03-03 PL PL10250378T patent/PL2308491T3/pl unknown
- 2010-03-03 ES ES10250378T patent/ES2395159T3/es active Active
- 2010-03-03 RS RS20110506A patent/RS51976B/en unknown
- 2010-03-03 EP EP11005708A patent/EP2377537A1/en not_active Withdrawn
- 2010-03-03 DK DK10250378.6T patent/DK2308491T3/da active
- 2010-03-03 EP EP10250378A patent/EP2308491B1/en active Active
- 2010-03-03 PT PT10250378T patent/PT2308491E/pt unknown
- 2010-03-03 SI SI201030011T patent/SI2308491T1/sl unknown
- 2010-08-17 CA CA2710014A patent/CA2710014C/en active Active
- 2010-08-23 AU AU2010212488A patent/AU2010212488B2/en not_active Revoked
- 2010-12-03 KR KR1020127018340A patent/KR101762465B1/ko active IP Right Grant
- 2010-12-03 KR KR1020117016135A patent/KR20110091816A/ko not_active Application Discontinuation
- 2010-12-03 EA EA201200574A patent/EA026869B1/ru not_active IP Right Cessation
- 2010-12-03 PE PE2012000449A patent/PE20121348A1/es not_active Application Discontinuation
- 2010-12-03 MX MX2012004528A patent/MX2012004528A/es active IP Right Grant
- 2010-12-03 WO PCT/US2010/058936 patent/WO2011069089A1/en active Application Filing
- 2010-12-03 TW TW099142294A patent/TWI440459B/zh not_active IP Right Cessation
- 2010-12-03 GE GEAP201012737A patent/GEP20166426B/en unknown
- 2010-12-03 TW TW101148844A patent/TW201315718A/zh unknown
- 2010-12-03 SG SG2012039624A patent/SG181128A1/en unknown
- 2010-12-03 US US13/513,472 patent/US8754109B2/en active Active
- 2010-12-03 JP JP2011544702A patent/JP5753094B2/ja active Active
- 2010-12-03 NZ NZ599246A patent/NZ599246A/en unknown
- 2010-12-03 EP EP20100835205 patent/EP2506849A4/en not_active Withdrawn
-
2011
- 2011-06-09 HK HK11105854.1A patent/HK1151725A1/xx unknown
- 2011-11-16 HR HR20110853T patent/HRP20110853T1/hr unknown
- 2011-11-22 CY CY20111101128T patent/CY1112075T1/el unknown
- 2011-12-15 US US13/326,971 patent/US8648098B2/en active Active
-
2012
- 2012-01-24 SM SM201200003T patent/SMT201200003B/it unknown
- 2012-04-04 IL IL219056A patent/IL219056A/en active IP Right Review Request
- 2012-04-10 ZA ZA2012/02553A patent/ZA201202553B/en unknown
- 2012-05-22 JP JP2012116700A patent/JP2012153734A/ja active Pending
-
2014
- 2014-05-19 JP JP2014103119A patent/JP2014144980A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201200574A1 (ru) | Терапия пирфенидоном и индукторы цитохрома р450 | |
| EA201200559A1 (ru) | Способы назначения терапии пирфенидоном | |
| PH12016502066A1 (en) | Methods of treating bladder cancer | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| MX2019009437A (es) | Tratamiento de mielosupresion. | |
| MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| UA111386C2 (uk) | Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ | |
| MX2009010984A (es) | Moduladores de heterociclo cinasa de anillo fusionado. | |
| PH12014502513A1 (en) | Nampt inhibitors | |
| MX2014013752A (es) | Inhibidores de nampt. | |
| EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
| TN2011000647A1 (en) | Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria | |
| EP2670763A1 (en) | Certain chemical entities, compositions, and methods | |
| MX348311B (es) | Inhibidores nampt. | |
| GEP201706621B (en) | Benzamides | |
| MX2015003701A (es) | Composiciones para tratamiento. | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| PH12017500563A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| IN2014DN03010A (ru) | ||
| WO2011116351A3 (en) | Methods and compositions for the treatment of cancer | |
| WO2012024670A3 (en) | Composition and methods for treating glioblastoma | |
| MX2015016167A (es) | Tratamiento de la vasculopatia coroidea polipoidal. | |
| MY161946A (en) | Pirfenidone therapy and inducers of cytochrome p450 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |